Showing results (51-60 of 57) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Nature Communications|October 15, 2024
Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trialJing Wu, Shilong Zhang, Shan Yu, et al.Nature Communications|August 23, 2024
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 studyXiaojing Xu, Luoyan Ai, Keshu Hu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 2023
Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 StudiesMichael C Heinrich, Xinhua Zhang, Robin L Jones, et al.Nature Communications|November 10, 2022
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junctionZhaoqing Tang, Yan Wang, Dan Liu, et al.European Journal of Cancer (Oxford, England : 1990)|July 20, 2023
Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trialQi Lin, Kefeng Ding, Ren Zhao, et al.The Oncologist|December 8, 2022
Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter StudyJian Li, Xinhua Zhang, Yanhong Deng, et al.Cancer Communications (London, England)|October 19, 2021
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II studyZhi Peng, Tianshu Liu, Jia Wei, et al.Pageof 6